Manufacturers Of Ozempic And Mounjaro Sued: A federal lawsuit filed on August 2, 2023 in the United States District Court Western District of Louisiana Lake Charles Division alleges, in part:
“Ozempic and Mounjaro [are] two injectable prescription medications that are used to control blood sugar in adults with type 2 diabetes.”
“Ozempic is also known as semaglutide. Ozempic works by stimulating insulin production and reducing glucose production in the liver helping to lower blood sugar levels.”
“Mounjaro is also known as tirzepatide. Mounjaro works by targeting the body’s receptors for GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1).”
“Ozempic and Mounjaro belong to a class of drugs called GLP-1 receptor agonists.”
“Gastroparesis is a condition that affects normal muscle movement in the stomach. Ordinarily, strong muscular contractions propel food through the digestive tract. However, in a person suffering from gastroparesis, the stomach’s motility is slowed down or does not work at all, preventing the stomach from emptying properly. Gastroparesis can interfere with normal digestion, cause nausea, vomiting, abdominal pain, abdominal bloating, severe dehydration, a
feeling of fulness after eating just a few bites, vomiting undigested food, undigested food that hardens and remains in the stomach, acid reflux, changes in blood sugar levels, lack of appetite, weight loss, malnutrition, and a decreased quality of life. There is no cure for gastroparesis.”
“Gastroenteritis refers to inflammation of the stomach and intestines. While viral gastroenteritis is also known as stomach flu, gastroenteritis may also be caused by ingesting medications. Its symptoms include vomiting, nausea, diarrhea, stomach cramps, muscle aches, headaches, and fever. Notably, vomiting and diarrhea can cause dehydration, which is the main complication of gastroenteritis, and which can lead to death.”
“Defendants acknowledge that gastrointestinal events are well known side effects of the GLP-1 class. However, Defendants have downplayed the severity of the gastrointestinal events caused by Ozempic and Mounjaro, never, for example, warning of the risk of gastroparesis (“paralyzed stomach”) or gastroenteritis.”
“From the date the Novo Nordisk Defendants received FDA approval to market Ozempic until the present time, the Novo Nordisk Defendants made, distributed, marketed, and/or sold Ozempic without adequate warning to Plaintiff’s prescribing physician(s) and/or Plaintiff that Ozempic was associated with and/or could cause severe gastrointestinal issues including gastroparesis and gastroenteritis.”
“From the date Eli Lilly received FDA approval to market Mounjaro until the present time, Eli Lilly made, distributed, marketed, and/or sold Mounjaro without adequate warning to Plaintiff’s prescribing physician(s) and/or Plaintiff that Mounjaro was associated with and/or could cause severe gastrointestinal issues, including gastroparesis and gastroenteritis.”
“Upon information and belief, Defendants knew of the association between the use of GLP-1 receptor agonists and the risk of developing severe gastrointestinal issues, including gastroparesis and gastroenteritis. Defendants’ knowledge derived from their clinical studies, case reports, and the medical literature, including the medical literature and case reports referenced above in this Complaint.”
“Upon information and belief, Defendants ignored the association between the use of GLP-1 receptor agonists and the risk of developing severe gastrointestinal issues, including gastroparesis and gastroenteritis.”
“Defendants’ failure to disclose information that they possessed regarding the association between the use of GLP-1 receptor agonists and the risk of developing severe gastrointestinal issues, including gastroparesis and gastroenteritis, rendered the warnings for this medication inadequate.”
“By reason of the foregoing acts and omissions, Plaintiff was and still is caused to suffer from severe gastrointestinal issues, as well as other severe and personal injuries which are permanent and lasting in nature, physical pain, and mental anguish, including diminished enjoyment of life, as well as the need for lifelong medical treatment, monitoring and/or medications, and fear of developing any of the above-named health consequences.”
The Defendants have yet to respond to the detailed allegations in the federal Complaint, which allegations are unproven at this time.
WE ARE CURRENTLY INVESTIGATING OZEMPIC AND MOUNJARO CLAIMS THROUGHOUT THE UNITED STATES.
If you or a loved one suffered injury or other harm from Ozempic or Mounjaro in the United States, you should promptly find a lawyer who may investigate your Ozempic or Mounjaro claims for you and who may represent you or your loved one in an Ozempic or Mounjaro case, if appropriate.
Visit our website or call us toll-free in the United States at 800-295-3959 to find Ozempic and Mounjaro attorneys who may assist you with your Ozempic or Mounjaro claim.
Turn to us when you don’t know where to turn.